Welcome to our dedicated page for Abivax S.A. SEC filings (Ticker: ABVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to find the next clinical milestone hidden in Abivax SA’s dense SEC paperwork? Biotech disclosures pack pages of immunology data, cash-runway tables, and dilution scenarios that matter to every ABVX shareholder. Whether you are tracking obefazimod’s Phase III progress or weighing financing risk, the details often sit deep inside a 20-F, a sudden 8-K, or a Form 4 showing an executive stock purchase.
Stock Titan turns those complex documents into clear insights. Our AI-powered summaries translate Abivax’s annual report 10-K simplified explanations, break down each quarterly earnings report 10-Q filing, and flag 8-K material events explained in plain language—minutes after they hit EDGAR. Need real-time alerts on Abivax insider trading Form 4 transactions? You’ll see executive stock transactions Form 4 with context, alongside cash-flow trends and R&D spend extracted automatically. From proxy statement executive compensation tables to shelf-registration details, every filing type is covered and refreshed continuously.
Investors use these distilled insights to: monitor Form 4 insider transactions in real time before key data releases; compare trial-related expenses quarter over quarter; and understand how secondary offerings might affect share count. If you have ever typed “understanding Abivax SEC documents with AI� or “Abivax earnings report filing analysis,� this page is your answer. Access the full library of Abivax SEC filings explained simply, drill into specific numbers with one click, and make decisions backed by complete, up-to-date information—without wading through hundreds of technical pages.
Oceaneering International (OII) Q2-25 10-Q highlights
- Revenue grew 4% YoY to $698.2 million; 93% was recognized over time.
- Gross margin expanded to 21.3%, lifting operating income 31% to $79.2 million (11.3% margin).
- Net income jumped 56% to $54.4 million; diluted EPS rose to $0.54 from $0.34.
- Year-to-date revenue increased 8% to $1.37 billion; operating income up 57% to $152.7 million.
- Operating cash flow remained negative at $(3.5) million, though improved from $(17.1) million a year ago; capex $56.4 million and buybacks $20.1 million cut cash to $434 million (-$63 million YTD).
- Net debt is modest at ~$51 million; full $215 million revolver undrawn.
- Energy portfolio delivered 19% margin: Subsea Robotics 29% (ROV utilization 67%, day-rates higher), OPG 15%, Manufactured Products 13%; IMDS steady at 6%.
- Aerospace & Defense Technologies revenue advanced 13% to $109.6 million with 15% margin.
- Manufactured Products backlog fell 28% YoY to $516 million; six contracts triggered $4.6 million in loss provisions.
- Inventory reserves rose $4.6 million; tax rate 30.6%. Company is assessing effects of the newly enacted One Big Beautiful Bill Act.
Etsy, Inc. (ETSY) has filed a Form 144 dated 24 Jul 2025 disclosing a proposed insider sale. CEO Josh Silverman intends to dispose of 140,000 common shares, to be brokered through UBS Financial Services. At the market price implied in the filing, the lot is valued at $9.1 million, equal to roughly 0.13% of the 104.28 million shares outstanding. The shares come from a same-day cash exercise of employee stock options and may be sold on or after 24 Jul 2025.
The notice also details Silverman’s recent activity: over the past three months he sold 195,998 shares across three transactions, generating $10.8 million in gross proceeds. Form 144 is only an advance notice—sales may or may not occur—but continued insider selling can create a modest overhang and may be read as a negative signal on near-term management outlook. No operational, earnings or guidance data accompany the filing.
DigitalBridge Group, Inc. (DBRG) � Form 4 insider filing
Chief Accounting Officer Tracey Teh reported a single transaction dated 07/21/2025. The issuer withheld 4,079 Class A common shares (code “F�) at $10.76 per share, equal to roughly $43,900, to satisfy payroll-tax obligations triggered by the vesting of a prior equity award. No open-market buy or sell order occurred.
After the withholding, Teh’s direct ownership stands at 64,976 Class A shares. No derivative positions were reported. Because the event reflects routine tax withholding rather than an investment decision, it carries minimal signaling value regarding management’s view of DBRG’s valuation and has no impact on the company’s fundamentals or liquidity.
FAQ
What is the current stock price of Abivax S.A. (ABVX)?
What is the market cap of Abivax S.A. (ABVX)?
What is Abivax SA's primary focus?
Which therapeutic areas does Abivax target?
What distinguishes Abivax in the biotech industry?
How does Abivax generate value with its business model?
Can you explain the significance of obefazimod?
How does Abivax build trust in its clinical research?
How does Abivax compare to other biotech companies?
